Efficacy analysis and adverse event management of selinexor in the treatment of relapsed/refractory multiple myeloma.
- 1Weifang People's Hospital, Shandong Second Medical University, Not applicable Weifang, Shandong, China.
Abstract
The treatment of relapsed/refractory multiple myeloma (RRMM) remains a significant clinical challenge, particularly for patients with multidrug resistance, who have a poor prognosis and limited therapeutic options. Selinexor, as the world's first oral selective inhibitor of nuclear export (SINE), targets the XPO1 protein, offering a novel treatment mechanism distinct from traditional agents for RRMM. This narrative review systematically synthesizes the mechanism of action of Selinexor and critically evaluates evidence from key clinical studies (such as the STORM and BOSTON trials). It focuses on discussing its clinical positioning across different scenarios and its combination strategies with commonly used regimens (e.g., SVd). It also addresses standardized, proactive management pathways for its characteristic adverse effects (e.g., thrombocytopenia, gastrointestinal reactions). These strategies are tailored to patient stratification (such as triple-/penta-refractory, elderly/frail patients). The aim is to provide clinicians with a practical, evidence-based reference for the safe and effective application of this drug to optimize treatment outcomes for RRMM patients.
Related
- PO048 | EFFICACY OF RITUXIMAB TREATMENT IN A CASE OF A RELAPSED AND REFRACTORY ACQUIRED VON WILLEBRAND DISEASE SECONDARY TO PRIMARY CUTANEOUS MARGINAL ZONE B-CELL LYMPHOMA
- Survival Outcomes with IL-2-Free Dinutuximab Beta Treatment Strategies With or Without 13-cis-Retinoic Acid in Relapsed or Refractory Neuroblastoma: An Exploratory Unanchored, Population-Adjusted Comparison of Two Prospective Cohorts
- Efficacy and safety of ifupinostat in relapsed or refractory diffuse large B-cell lymphoma: a multicenter, single-arm phase 2 study.
- Surgical Management and Outcomes of Relapsed and Refractory Hepatoblastoma: An Institutional Case Series.
- Pretreatment Prognostic Nutritional Index Is Associated with Treatment Response and Survival in Patients with Relapsed or Refractory Non-Hodgkin Lymphoma Receiving CAR-T Cell Therapy
BibTeX
@article{kuang2026efficacy,
title = {{Efficacy analysis and adverse event management of selinexor in the treatment of relapsed/refractory multiple myeloma.}},
author = {Zengli Kuang and Yu Chen and Cuiai Ren},
journal = {Frontiers in medicine},
year = {2026},
month = oct,
doi = {10.3389/fmed.2026.1927209},
url = {https://europepmc.org/article/MED/42909298},
note = {CC BY},
}
RIS
TY - JOUR
TI - Efficacy analysis and adverse event management of selinexor in the treatment of relapsed/refractory multiple myeloma.
AU - Zengli Kuang
AU - Yu Chen
AU - Cuiai Ren
PY - 2026
DA - 2026/10/06
JO - Frontiers in medicine
DO - 10.3389/fmed.2026.1927209
UR - https://europepmc.org/article/MED/42909298
AB - The treatment of relapsed/refractory multiple myeloma (RRMM) remains a significant clinical challenge, particularly for patients with multidrug resistance, who have a poor prognosis and limited therapeutic options. Selinexor, as the world's first oral selective inhibitor of nuclear export (SINE), targets the XPO1 protein, offering a novel treatment mechanism distinct from traditional agents for RRMM. This narrative review systematically synthesizes the mechanism of action of Selinexor and critically evaluates evidence from key clinical studies (such as the STORM and BOSTON trials). It focuses on discussing its clinical positioning across different scenarios and its combination strategies with commonly used regimens (e.g., SVd). It also addresses standardized, proactive management pathways for its characteristic adverse effects (e.g., thrombocytopenia, gastrointestinal reactions). These strategies are tailored to patient stratification (such as triple-/penta-refractory, elderly/frail patients). The aim is to provide clinicians with a practical, evidence-based reference for the safe and effective application of this drug to optimize treatment outcomes for RRMM patients.
SN - 2296-858X
ER -